Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesAgomAb Therapeutics NV American Depositary Shares

AgomAb Therapeutics NV American Depositary Shares

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
7.6005 USD -0.03 ( 0.45%)
Last update at 2026-11-09T15:43:00Z
VOLUME
127913
Market Cap
598.86M

Momentum Score

…

AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials. It also develops AGMB-101, a HGF-mimetic monoclonal antibody that acts through agonism or stimulation of the MET receptor and has demonstrated antifibrotic and regenerative activity in preclinical models. The company was incorporated in 2017 and is headquartered in Antwerp, Belgium.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
7.50
Low
8.24
High
52 Week Price Range
8.75
Low
17.82
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

AgomAb Therapeutics NV is a clinical-stage biotechnology company developing antibody-based therapeutics and advancing a pipeline through clinical trials and collaborations. Long-term growth drivers include clinical and regulatory progress, potential licensing or partnership deals, and the commercialisation of differentiated, longer-acting biologics that may address high-demand therapeutic areas; investors may find exposure to an early-stage biologics platform attractive for long-term upside potential.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
7.63
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.01
ROE
-39.22%
Net Debt
-85.16M
ROCE
-46.25%
Diluted EPS TTM
-1.57

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Type yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Income before tax -62.55M -46.26M -12.01M -10.81M
Net income -62.55M -46.27M -11.39M -8.14M
Selling general administrative 12.57M 9.82M 6.00M 4.49M
Gross profit -0.21M - - -
Reconciled depreciation 0.22M 0.31M 0.10M 0.02M
Ebit -62.49M -46.20M -11.98M -10.76M
Ebitda -62.27M -45.88M -11.88M -10.74M
Depreciation and amortization 0.22M 0.31M 0.10M 0.02M
Operating income -59.27M -48.02M -31.19M -22.63M
Other operating expenses 59.27M 48.02M 31.19M 22.63M
Interest expense 0.06M 0.07M 0.03M 0.04M
Tax provision 0.00M 0.00M -0.62M -2.66M
Interest income 1.61M 1.22M 0.24M 0.07M
Net interest income 1.55M 1.14M 0.21M 0.03M
Income tax expense 0.00M 0.00M -0.62M -2.66M
Total revenue 0.00M 0.00M 0.00M 0.00M
Total operating expenses 59.27M 48.02M 31.19M 22.63M
Cost of revenue 0.21M - - -
Total other income expense net -3.27M 1.76M 19.18M 11.83M
Net income from continuing ops -62.55M -46.27M -11.39M -8.14M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 153.71M 206.36M 171.26M 101.00M 84.00M
Intangible assets 23.62M 20.11M 20.11M 20.11M 20.11M
Other current assets -0.06M - 0.00M - -
Total liab 22.80M 18.28M 19.82M 34.75M 41.63M
Total stockholder equity 130.90M 188.08M 151.44M 66.25M 42.36M
Other current liab 8.98M - 1.23M 23.32M 31.74M
Common stock 223.07M - - - -
Capital stock 223.07M 223.07M 174.71M 110.41M 84.40M
Retained earnings -181.71M -119.18M -72.83M -61.44M -44.82M
Good will 10.11M 8.61M 8.61M 8.61M 8.61M
Cash 86.42M 171.46M 122.40M 27.67M 53.59M
Total current liabilities 18.59M 9.13M 10.88M 29.72M 33.71M
Current deferred revenue 1.46M - - - -
Net debt -85.16M - - - -
Short term debt 0.25M - - - -
Short long term debt total 1.25M - - - -
Other stockholder equity 90.51M - - - -
Total current assets 121.24M 173.84M 139.47M 71.08M 54.43M
Long term investments 0.01M 0.01M 0.01M 0.01M 0.15M
Short term investments 30.10M - 0.00M 40.00M 0.00M
Net receivables 4.78M - - - -
Long term debt - - - - 0.69M
Accounts payable 7.63M 5.95M 6.83M 3.90M 1.06M
Accumulated other comprehensive income -0.97M - - - -
Non currrent assets other -2.86M - -0.00M - -
Non current assets total 32.47M 32.51M 31.79M 29.91M 29.57M
Capital lease obligations 1.25M 1.54M 1.62M 0.06M 0.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Type yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Investments -30.00M 0.00M 40.00M -40.00M
Total cashflows from investing activities -33.00M - - -
Net borrowings -0.34M -0.16M -0.10M -0.72M
Total cash from financing activities -0.34M 96.76M 79.32M 37.63M
Net income -62.55M -46.27M -11.39M -8.14M
Change in cash -85.04M 49.26M 94.73M -25.92M
Begin period cash flow 171.46M 122.40M 27.67M 53.59M
End period cash flow 86.42M 171.46M 122.40M 27.67M
Total cash from operating activities -51.74M -46.83M -24.59M -18.97M
Issuance of capital stock 0.00M 97.06M 79.87M 38.38M
Depreciation 0.22M 0.31M 0.10M 0.02M
Capital expenditures 0.00M 0.68M 0.00M 0.00M
Change in working capital 0.41M -1.28M 4.12M 1.41M
Stock based compensation 5.36M 1.07M 2.16M 2.21M
Other non cash items 4.83M -1.14M -0.22M 0.06M
Free cash flow -51.74M -47.50M -24.59M -18.97M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
AGMB
AgomAb Therapeutics NV American Depositary Shares		 -0.03
0.45%		 7.60 - - - 1.96
NVO
Novo Nordisk A/S		 0.47
1.18%		 40.78 41.58 31.15 2.13 32.99
VRTX
Vertex Pharmaceuticals Inc		 0.34
0.06%		 547.43 30.22 24.27 10.36 6.50
REGN
Regeneron Pharmaceuticals Inc		 8.76
0.97%		 913.11 29.07 20.12 7.57 3.82
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12

Profile*

AgomAb Therapeutics NV American Depositary Shares

AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials. It also develops AGMB-101, a HGF-mimetic monoclonal antibody that acts through agonism or stimulation of the MET receptor and has demonstrated antifibrotic and regenerative activity in preclinical models. The company was incorporated in 2017 and is headquartered in Antwerp, Belgium.

Posthoflei 1/6, Antwerp, Belgium, 2600

32 3 318 91 70

https://www.agomab.com

62

Name Title Year Born
Dr. Tim Knotnerus MSc, Ph.D. CEO & Executive Director 1983
Mr. Paolo Michieli Ph.D. Founder, Senior Advisor & Member of Scientific Advisory Board NA
Mr. Pierre Kemula B.Sc. Chief Financial Officer 1974
Sofie Van Gijsel Vice President of Investor Relations NA
Ms. Ellen Lefever General Counsel 1985
Dr. Philippe Wiesel M.D. Chief Medical Officer 1967
Dr. Paul Van Der Horst Ph.D. Chief Business Officer 1988
Dr. Andrea Sáez Borderías Ph.D. Chief Development Officer 1982

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.93
+37.83%
MOON
CAD 4.86
+10.20%
HG
CAD 4.43
+9.93%
EPRX
CAD 10.57
+8.86%
NUAG
CAD 8.66
+8.79%
CSU
CAD 3257.60
-7.63%
DIV
CAD 3.85
-5.53%
TOI
CAD 99.00
-5.52%
BSX
CAD 0.82
-4.65%
LMN
CAD 26.79
-4.63%

Equity Sectors*

  • Basic Materials

    +3.88%

  • Communication Services

    -1.14%

  • Consumer Cyclical

    +0.75%

  • Consumer Defensive

    -0.36%

  • Energy

    +2.16%

  • Financial Services

    +1.33%

  • Healthcare

    +1.50%

  • Industrials

    +2.97%

  • Real Estate

    +0.41%

  • Technology

    +1.27%

  • Utilities

    +1.09%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…